Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
University of California, San Francisco
With
This was intended to be a phase I/II study of ceritinib and trametinib in Stage IIIB or IV ALK rearranged NSCLC. The phase I portion is a standard 3+3 dose escalation study starting at dose level 1 and will be open to any patient with ALK-rearranged, or ROS-1 rearranged NSCLC. The study was terminated before Phase II was initiated. The study did not open Phase II for enrollment into the planned cohorts: * Cohort A (ALKi Naïve) * Cohort B (Post-crizotinib PD) * Cohort C (PD second line ALK TKI (e.g., alectinib, ceritinib, PF-06463922 or - AP21163) Only participants in Phase 1 were enrolled. Patients may continue treatment for up to 24 months from the time of study entry, and will receive 12 months of follow-up following completion of the drugs.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted